En EGRIFTA ASSIST® tenemos consejeros, y una enfermera disponible para asistir en Español.
Why Talk With Your Healthcare Provider About Your HIV-Related Excess Abdominal Fat?
Because if it's bothering you, it's worth talking about.
And because there's EGRIFTA®
(tesamorelin for injection). The only FDA-approved medicine shown to reduce excess
abdominal fat in HIV-infected patients with lipodystrophy. The excess abdominal
fat is called visceral adipose tissue (VAT).
EGRIFTA® is an injectable prescription
medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy.
EGRIFTA® contains a growth hormone-releasing
- The impact and safety of EGRIFTA®
on cardiovascular health has not been studied.
EGRIFTA® is not indicated for weight
- It is not known whether taking EGRIFTA®
helps improve compliance with anti-retroviral medications.
- It is not known if EGRIFTA® is safe
and effective in children. EGRIFTA®
is not recommended to be used in children.
You are encouraged to report side effects of prescription
drugs to the FDA. Call 1-800-FDA-1088 or visit www.fda.gov/medwatch.
This information is not intended to replace discussions with your doctor. For additional
information about EGRIFTA®, please
Prescribing Information, Patient Information, and Patient Instructions for
Use, and talk to your doctor. You can also call toll-free 1-844-EGRIFTA
(347-4382). EGRIFTA® is available
Ask your healthcare provider for more information about
To get the discussion
started with your healthcare provider, download this guide
about HIV-related Excess Abdominal Fat. If you have been prescribed EGRIFTA®
and have questions about product support,
please call EGRIFTA ASSIST®
at 1-844-EGRIFTA (347-4382).